OncoSil Medical (OSL) Stock Price, News & Analysis

Company Overview

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2.17 million shs
• Average Volume: N/A
• Market Capitalization: A$32.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OSL Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of OncoSil Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoSil Medical investors own include Invictus Energy (IVZ), Citizens (CIA), Red Mountain Mining (RMX), National Australia Bank (NAB), Rivian Automotive (RIVN), Blackmores (BKL) and Twitter (TWTR).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: ASX:OSL
• CIK: N/A
• Web: www.oncosil.com.au
• Phone: 61 2 9223 3344
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$11.91 million
• Net Margins: -2,395.37%
• Pretax Margin: N/A
• Return on Equity: -280.65%
• Return on Assets: -82.34%

Debt

• Debt-to-Equity Ratio: 1.49
• Current Ratio: 3.26
• Quick Ratio: 6.89

Sales & Book Value

• Annual Sales: A$1.57 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 10.91
• Book Value: A$0.00 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,780,000,000
• Free Float: N/A
• Market Cap: A$32.25 million
• Optionable: Not Optionable
• Beta: 0.91